UPDATE | October 13, 2026

What are the key bottlenecks preventing rapid adoption of novel technologies?

  • MAIL

Our latest Pharma's Almanac commentary features David Kang, Director of DI Governance, discussing the bottlenecks slowing advanced biomanufacturing adoption. Despite the promise of digital twins and automated processing, three key barriers stall industry-wide transition: regulatory uncertainty for unproven platforms, the high capital cost of retrofitting legacy facilities, and a talent gap bridging bioprocessing with data science.


Read our full commentary to learn how we can overcome these barriers.

Our latest Pharma's Almanac commentary features David Kang, Director of DI Governance, discussing the bottlenecks slowing advanced biomanufacturing adoption. Despite the promise of digital twins and automated processing, three key barriers stall industry-wide transition: regulatory uncertainty for unproven platforms, the high capital cost of retrofitting legacy facilities, and a talent gap bridging bioprocessing with data science.


Read our full commentary to learn how we can overcome these barriers.

Share article

  • MAIL

Related Content

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required